FDA News Release. The U.S. Food and Drug Administration approved Rapamune (sirolimus), to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women…
The 2015 International LAM Scientific and Patient Conference will take place in Chicago, USA, from March 27th to 29th 2015. Find out more on the LAM…
On November 13 -15 an exceptional group of biomarker scientists with diverse expertise gathered in Atlanta, GA, at the LAM Biomarker Innovation Summit. This meeting…
For the second year in a row Antoine Salles, Chef and owner of French Bistrot “Touquet” in O’Connell St in Auckland City, will run the Auckland…
The LAM Trust invites you to the Annual Gift Of Music Charity Concert by the Renowned Concert Pianist Mi-Yeon I. Founded by Mi-Yeon I, the aim is…
Following on from the very successful Short Course on Rare Lung Disease, hosted by the Australian Lung Foundation on 9 and 10 August in Sydney,…
LAM Therapeutics launches operations to develop drugs for rare lung disease, Lymphangioleiomyomatosis (LAM). LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs…
The Impact of Rare Diseases: in New Zealand and Internationally. Rare Diseases are conditions that affect a small portion of the population but are often…
The Annual LAM patient and scientific meeting was held in Cincinnati, Ohio, USA, April 12/13/14 2013. More than 100 women with LAM from a dozen…
Bronwyn Gray, the NZ LAM Trust’s Director met recently in Melbourne with LAM patient, Heather Telford, immediate past president of LARA (LAM Austrlasia Research Alliance)…